An inflammatory subtype of pancreatic ductal adenocarcinoma is associated with poor prognosis and increased perioperative mortality

作     者：Benzing Christian Klein Fritz Pelzer Uwe Sinn Marianne Pratschke Johann Bahra Marcus Benzing Christian;Klein Fritz;Pelzer Uwe;Sinn Marianne;Pratschke Johann;Bahra Marcus

作者机构：Campus Charité-Mitte and Campus Virchow KlinikumCharité-Universitätsmedizin BerlinBerlinGermany Department of HematologyOncology and Tumor ImmunologyCharité-Universitätsmedizin BerlinBerlinGermany 

出 版 物：《Journal of Pancreatology》 (胰腺病学杂志（英文）)

年 卷 期：2019年第2卷第3期

页      面：107-112页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Cholangitis CRP Inflammatory carcinoma PDAC 

摘      要：Pancreatic ductal adenocarcinoma(PDAC)is a malignancy characterized by an aggressive tumor *** present analysis seeks to identify and analyze a cohort that meets criteria forinflammatoryPDAC(IPDAC).All patients who underwent a curative resection for PDAC at our institution between 1989 and 2015 were included in the retrospective *** with histological proven adenocarcinoma and elevated C-reactive protein(CRP)(≥6 mg/L)serum concentrations,but no other suspicion of infection were *** provide a matched control group with normal CRP serum levels from the same patient ***-six(6.8%)of 532 patients meet our criteria for an IPDAC group ***-hospital(30 days)mortality was 13.9%in the IPDAC group vs 0%in the control group(P=.020).Median follow-up was 183.8 months(standard deviation[SD]=53.3,range 14.3-285.4).Median overall survival was 8.5 months(SD=16.8,range 0.3-89.6)in the IPDAC group and 24.8 months(SD=19.4,range 0.7-80.4)in the control group(P=.002).Patients indicating an IPDAC in our cohort had a significantly and clinical meaningful decreased overall survival and a higher perioperative morbidity and mortality.